Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Table 2 Overall survival in the overall population by volume of disease and time of metastatic disease presentation

Cohorts	N. patients (%)	N. deaths (%)	OS (%) (SE)	p-value*	Median OS (months) (95% CI)	HR (95% CI)	p-value°
LV/PLT LV/DN HV/PLT HV/DN	157 (37.6) 87 (20.9) 64 (19.3) 109 (26.2)	59 (28.6) 39 (18.9) 40 (19.4) 68 (33.1)	32.4 (8.9) 16.3 (9.1) 20.9 (6.6) 9.9 (5.4)	0.0001	61.9 (50.0–73.8) 47.9 (43.4–52.5) 27.5 (21.4–33.6) 27.8 (19.8–35.8)	1 (ref) 1.34 (0.90–2.02) 2.84 (1.90–4.26) 2.63 (1.85–3.74)	0.15 0.0001 0.0001

CI confidence interval, DN de-novo, HR hazard ratio, HV high volume, LV low volume, OS overall survival, PLT prior local therapy, SE standard error
^*p-value from log-rank test
°p-value from univariate Cox regression analysis

ISSN: 1479-5876